New drug targets Hard-to-Treat cancers in early trial
NCT ID NCT07444814
First seen Mar 29, 2026 · Last updated May 15, 2026 · Updated 4 times
Summary
This early-stage study tests a new drug called HWK-007 in people with advanced solid tumors, such as certain ovarian, endometrial, and lung cancers. The drug is designed to target and attack cancer cells that have a specific marker (PTK7). The main goals are to find the safest dose and to check for side effects. About 226 adults will take part, and the study is currently recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fred Hutchinson Cancer Center
NOT_YET_RECRUITINGSeattle, Washington, 98109, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hackensack University Medical Center - John Theurer Cancer Center
NOT_YET_RECRUITINGHackensack, New Jersey, 07601, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NEXT - Oncology - Houston
RECRUITINGHouston, Texas, 77054, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
NEXT Oncology - Austin
RECRUITINGAustin, Texas, 78758, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NEXT Oncology - Virginia Cancer Specialists
RECRUITINGFairfax, Virginia, 22031, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Roswell Park Comprehensive Care Center
NOT_YET_RECRUITINGBuffalo, New York, 14263, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
START - Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
START - San Antonio
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
St. Francis Medical Center (OSF Healthcare)
NOT_YET_RECRUITINGPeoria, Illinois, 61637, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
UCLA - Hematology/Oncology Clinical Research Unit
NOT_YET_RECRUITINGLos Angeles, California, 90095, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University Hospital - Cleveland Medical Center
NOT_YET_RECRUITINGCleveland, Ohio, 44106, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Arkansas
NOT_YET_RECRUITINGLittle Rock, Arkansas, 72205-7199, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.